Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 8/20 | 0.48 |
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769238 | 0.96 | MAOA (0.53) | PARP1PARP10MAOAMAOBCYP2A6 | |
| SCHEMBL29446042 | 0.96 | MAOA (0.53) | PARP1PARP10MAOAMAOBCYP2A6 | |
| SCHEMBL29443089 | 0.88 | PBRM1 (0.59) | PARP1PARP10SRD5A1PBRM1ACHE | |
| SCHEMBL1150109 | 0.88 | PBRM1 (0.59) | PARP1PARP10SRD5A1PBRM1ACHE | |
| SCHEMBL2585151 | 0.84 | MAOA (0.59) | MAOAMAOBCYP2A6SRD5A1PRKCI | |
| SCHEMBL5211345 | 0.82 | HSD17B1 (0.53) | PARP1PARP10MAOAMAOBCYP2A6 | |
| SCHEMBL315877 | 0.80 | MAOA (0.61) | MAOAMAOBCYP2A6SRD5A1PRKCI | |
| SCHEMBL6835462 | 0.78 | PARP1 (0.44) | PARP1PARP10MAOAMAOBCYP2A6 | |
| SCHEMBL6835460 | 0.78 | PARP1 (0.44) | PARP1PARP10MAOAMAOBCYP2A6 | |
| SCHEMBL16821225 | 0.78 | PARP10 (0.50) | PARP10MAOAMAOBCYP2A6PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9520574-B2 | Electroluminescent devices based on phosphorescent iridium and related group VIII metal multicyclic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-13 | — | — | US | disclosed |
| US-9520574-B2 | Electroluminescent devices based on phosphorescent iridium and related group VIII metal multicyclic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-13 | — | — | US | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130082248-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-04-04 | — | — | US | disclosed |
| US-20130082248-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-04-04 | — | — | US | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011134013-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2011-11-03 | — | — | WO | disclosed |
| EP-1741693-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | NAGOYA IND SCIENCE RES INST (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2001002379-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-6146811-A | Photoresist using dioxaspiro ring-substituted acryl derivatives | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2000-11-14 | — | — | US | disclosed |
| CN-1193017-A | Sulfamide-substituted condensed seven-membered ring chemical compound, use as medicine and medicinal preparation containing same | HOECHST AG (DE) | 1998-09-16 | — | — | CN | disclosed |
| EP-0861836-A1 | Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-02 | — | — | EP | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0601249-A1 | Benzocycloheptene derivative and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5252589-A | Inhibits contraction of urinary bladder | TANABE SEIKAYU CO., LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | PARP1 3065/4885PARP10 4194/4885MAOA 251/4885 |
| US-20130082248-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | ICOSLG, ETV6, ROS1 | PARP1 536/4885PARP10 2300/4885MAOA 2542/4885 |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | PARP1 1521/4885PARP10 2021/4885MAOA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.